- ARWR: Multiple Important Clinical Readouts in 2H26
May 12, 2026
By David Bautz, PhD
NASDAQ: ARWR
READ THE FULL ARWR RESEARCH REPORT
Business Update
Update on REDEMPLO® Launch
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) launched REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS) following its approval by the U.S. FDA in November 2025. FCS is an orphan indication with approximately 6,500 individuals affected in the U.S. Following an initial strong start to the launch, the momentum has continued through the first quarter of 2026, with approximately 30 new prescriptions being written each week. Interestingly, of the approximately 400 prescriptions having been written thus far since launch, approximately 10-15% of those have been for patients switching from Ionis Pharmaceuticals Tryngolza® (olezarsen).
Arrowhead has lowered the wholesale acquisition cost (WAC) of REDEMPLO to $45,000 per year, which was done in response to Ionis lowering the WAC of Tryngolza to $40,000 per year ahead of a possible approval for the treatment of severe hypertriglyceridemia (SHTG), for which there is a PDUFA date of June 30, 2026. We believe that Arrowhead is justified in keeping the premium in place for REDEMPLO compared to Tryngolza for the following reasons: the depth of TG reduction (~80% reduction from baseline in the Phase 3 PALISADE trial); the numerical decrease in pancreatitis in PALISADE; no contraindications, warnings, or precautions on the label; and only 4 injections per year. The premium price may be further justified if a decrease in pancreatitis is seen in the SHASTA trials later this year.
Since its approval in the U.S., the company has gotten positive regulatory actions in four additional jurisdictions: approvals from The Australian Therapeutic Goods Administration, The Chinese National Medical Products Administration, and Health Canada. In addition, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion and is recommending the approval of REDEMPLO. Arrowhead will be launching REDEMPLO independently later this year in Canada and, if approved, in select EU countries along with the UK. In Greater China, REDEMPLO will be marketed by Sanofi.
Multiple Data Readouts in 2H26
Looking at the company’s pipeline, we anticipate four important clinical readouts occurring during the rest of 2026:
The SHASTA-3 and SHASTA-4 trials of plozasiran in SHTG patients are expected to readout in the third quarter of 2026. Positive results from the trials will support the supplemental NDA (sNDA) for the treatment of SHTG and increase the number of treatable patients with plozasiran.
Story Continues
Early data from the ongoing Phase 1/2 clinical trial of ARO-DIMER-PA in patients with mixed hyperlipidemia are expected in the third quarter of 2026. This will be the first look at clinical data for an RNAi molecule that is designed to simultaneously silence the expression of two proteins. Positive results, signified by a reduction in levels of PCSK9 and APOC3 (and subsequent reductions in LDL-cholesterol and TGs), would both support the advancement of ARO-DIMER-PA along with providing proof-of-concept for the company’s dimer platform and pipeline. Arrowhead has indicated that additional dual-functional dimers will be entering the clinic in 2027.
Early data from the ongoing Phase 1/2 trial of ARO-MAPT are expected late in the third quarter or early in the fourth quarter of 2026. This is the first candidate from the company’s CNS platform that is designed to deliver RNAi molecules to the brain via subcutaneous administration. ARO-MAPT targets the tau protein, which is a potential therapeutic target for Alzheimer’s and other Tauopathies. If these data are positive, the company intends to rapidly expand its CNS pipeline toward the end of 2026.
Clinical updates are anticipated for ARO-INHBE and ARO-ALK7 throughout the second half of 2026. For ARO-INHBE, the company intends to present additional data at various conferences and initiate a Phase 2 study. For ARO-ALK7, we anticipate additional data from the ongoing Phase 1/2 clinical trial. Investor enthusiasm for INHBE appears to have waned following the release of 6-month data for WVE-007 by Wave Life Sciences Ltd., however, Arrowhead has stated from the beginning that they believe modalities that target the INHBE/ALK7 axis would need to be part of a combination therapy with a GLP-1, particularly in type 2 diabetes patients. Thus, we are cautiously optimistic about the company’s path forward with ARO-INHBE and ARO-ALK7, given that they are being studied in combination with tirzepatide.
Licensing Agreement with Madrigal for ARO-PNPLA3
On May 5, 2026, Arrowhead announced an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, which is designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). PNPLA3 has strong genetic and preclinical validation in patients who carry the I148M mutation, which is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis, and cirrhosis. Results from a Phase 1 study of ARO-PNPLA3 in 55 patients with metabolic dysfunction-associated fatty liver disease (MAFLD) who were either homozygous or heterozygous carriers of the PNPLA3 I148M variant showed reductions in liver fat of up to 46% at 12 weeks following a single dose of the highest dose level tested of ARO-PNPLA3.
At closing, Madrigal will pay Arrowhead an upfront payment of $25 million. Arrowhead will also be eligible to receive development, regulatory, and sales milestone payments of up to $975 million, along with tiered royalties on commercial sales ranging from high-single digits to mid-teens.
Financial Update
On May 7, 2026, Arrowhead announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026. The company reported revenue of approximately $74 million for the second quarter of fiscal year 2026 compared to approximately $543 million for the second quarter of fiscal year 2025. The revenue for the current quarter was driven primarily by the license and collaboration agreements with Sarepta and Novartis, which includes 28 million from the ongoing recognition of the initial Sarepta consideration, 10 million related to reimbursement of incurred preclinical collaboration program costs, and 4 million for clinical supply provided to them under a clinical supply agreement. In addition, the company recognized $20 million of the $200 million upfront payment received from Novartis in October. Arrowhead also recorded $11 million related to the Asset Purchase Agreement between Sanofi and Visirna, the company’s majority owned subsidiary in China, to develop and commercialize plozasiran in Greater China. While not broken down specifically, revenues from the sale of REDEMPLO totaled approximately $1 million in the second quarter of fiscal year 2026.
R&D expenses for the second quarter of fiscal year 2026 were $173.3 million compared to $133.0 million for the second quarter of fiscal year 2025. The increase was primarily driven by the ongoing progression of the Phase 3 registrational studies for plozasiran in SHTG, along with the early-stage pipeline programs, including ARO-DIMER-PA and ARO-MAPT. G&A expenses for the second quarter of 2026 were $41.7 million compared to $28.4 million for the second quarter of fiscal year 2025. The increase was primarily due to ongoing investments to support the commercialization of REDEMPLO.
Arrowhead exited the second quarter of fiscal year 2026 with over one billion in cash, cash equivalents, and investments. Notable inflows in the quarter included the $200 million that the company earned for the DM1 second milestone from Sarepta, which was received in January 2026, along with the $50 million anniversary payment received from Sarepta. In addition, it includes the financing transaction that the company undertook in January 2026, consisting of a concurrent offering of convertible senior notes ($625 million of 0.00% convertible senior notes due 2032) and common stock (3,100,776 shares at a price of $64.50), along with associated capped call transactions.
Conclusion
Arrowhead’s stock has had a tremendous run over the past year, going from a low near $13 to currently over $70. So what will continue to drive it forward through 2026 and beyond? We believe it will be the SHTG results, which we are confident will show both best-in-class TG lowering along with a strong signal for decreasing the risk of pancreatitis, that will help to differentiate REDEMPLO from Tryngolza. The ARO-MAPT data could also be a game changer, with positive results providing both proof-of-concept for targeting tau protein and for the company’s CNS platform. Lastly, the DIMER data could lead to a unique therapy for the approximately 20 million individuals in the U.S. living with mixed hyperlipidemia, along with ushering in the next wave of dual targeting RNAi therapies. Arrowhead continues to perform at a high level, and we would be buyers of the stock on any pullback. Our valuation is now $85.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
View Comments
- A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth
May 10, 2026
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Madrigal Pharmaceuticals (MDGL) is back in focus after its first quarter 2026 earnings, where Rezdiffra delivered 127% year over year net sales growth to US$311.3 million, while the company still reported a US$94.4 million net loss.
See our latest analysis for Madrigal Pharmaceuticals.
The stock has been volatile, with a 1-day share price decline of 0.90%, a 90-day share price return of 11.99%, and a 1-year total shareholder return of 78.54% as Rezdiffra sales and pipeline updates remain in focus.
If you are looking for more ideas in healthcare as MASH treatments gain attention, it may be a good time to scan for other opportunities using our 35 healthcare AI stocks
With Madrigal trading around US$534.86 and analysts setting a wide range of higher targets, the key question for you is simple: is the current price still attractive, or is the market already factoring in most of the future growth?
Most Popular Narrative: 20.3% Undervalued
Against Madrigal Pharmaceuticals' last close of $534.86, the most followed narrative pegs fair value at $671.07, framing the stock as materially mispriced based on future cash flows.
The analyst price target for Madrigal Pharmaceuticals has been revised higher to $671.07, up from $603.47. Analysts now factor in updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E, following recent research that highlights both enthusiasm for Rezdiffra's commercial potential and some valuation concerns.
Read the complete narrative.
Curious what supports that higher fair value? The narrative leans heavily on rapid top line expansion, rising margins and a richer future earnings multiple. The exact mix of growth, profitability and discounting quietly does the heavy lifting.
Result: Fair Value of $671.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story can change quickly if competition from GLP 1 drugs eats into Rezdiffra uptake or if payer pushback compresses pricing and margins.
Find out about the key risks to this Madrigal Pharmaceuticals narrative.
Next Steps
With sentiment split between strong Rezdiffra momentum and real execution risks, it makes sense to move quickly and weigh the trade off for yourself using 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with just one stock, you risk leaving better opportunities on the table. Use curated screeners to quickly surface ideas that genuinely fit your style.
Story Continues
Target potential mispricings by scanning companies that look attractively valued using the 51 high quality undervalued stocks. Strengthen your income side by focusing on companies with higher yields and resilient payouts through the 12 dividend fortresses. Dial down portfolio stress by concentrating on financially steady companies using the 71 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MDGL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 5,312 shares of Madrigal’s common stock, 17,589 time-based restricted stock units and 1,839 performance-based restricted stock units. Options have an exercise price of $513.72 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. Performance-based restricted stock units are earned based on the total shareholder return of Madrigal relative to a defined peer group over a three year period and, to the extent earned, will cliff vest in the first quarter of 2029. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
View Comments
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026 · globenewswire.com
CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.
- MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
May 7, 2026
CONSHOHOCKEN, PA., MAY 07, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON MAY 1, 2026 TO 47 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
May 7, 2026
Madrigal Pharmaceuticals MDGL reported first-quarter 2026 loss of $3.25 per share, narrower than the Zacks Consensus Estimate of a loss of $3.61. In the same quarter last year, the company had incurred a loss of $2.61 per share.
In the first quarter, MDGL generated total revenues of $311.3 million, up significantly year over year, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved in 2024. The metric beat the Zacks Consensus Estimate of $301 million. Rezdiffra is the first marketed drug in MDGL’s portfolio, which was launched in April 2024 and posted significant year-over-year growth, driven by increased demand.
Madrigal shares gained 7.4% on Wednesday, as investors were impressed by the better-than-expected earnings results.
MDGL’s Q4 Results in Detail
In March 2024, the FDA granted accelerated approval to Rezdiffra, making it the first and currently the only approved therapy for the MASH indication. The eligible patient population includes adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Rezdiffra has also received conditional approval as the first and only therapy in the EU to treat adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis. Per Madrigal, more than 42,250patients are receiving the treatment as of March 31, 2026, up 2.5 times from first-quarter 2025, reflecting continued strong physician adoption and high patient demand.
During the quarter, research and development expenses more than doubled to $108.7 million in the first quarter of 2026. The massive increase can be primarily attributed to one-time, upfront business development expenses of $54.3 million.
Year to date, Madrigal shares have lost 7.3% against the industry’s 0.9% growth.Zacks Investment Research
Image Source: Zacks Investment Research
Selling, general and administrative expenses also nearly doubled in the reported quarter to $268.5 million. This exponential rise was on account of increased commercial launch activities for Rezdiffra, including significant increases in headcount to support marketing efforts.
Madrigal had cash, cash equivalents and marketable securities worth $817.9 million as of March 31, 2026, compared with $988.6 million as of Dec. 31, 2025.
MDGL’s Pipeline & Other Updates
As the FDA and EU approved Rezdiffra under the accelerated pathway, the continued approval will be based on promising long-term safety and efficacy data from the pivotal phase III MAESTRO-NASH biopsy study. This late-stage study, which provided the data for the drug's accelerated approval for MASH, is ongoing as an outcomes study, with data expected in 2028. The goal is to generate confirmatory 54-month data to verify the drug's clinical benefits and support full approval for the noncirrhotic MASH indication.
Story Continues
In addition to the study, a second phase III outcomes study (MAESTRO-NASH OUTCOMES) is underway, evaluating the progression to liver decompensation events in patients with compensated MASH cirrhosis treated with Rezdiffra compared with placebo. Top-line data is expected in 2027. A positive outcome from this study is also expected to support the full approval of Rezdiffra for noncirrhotic MASH and expand the eligible patient population for Rezdiffra with an additional indication.
The open-label extension (OLE) arm of the MAESTRO-NAFLD-1 study is also currently evaluating the drug in patients with compensated MASH cirrhosis. In 2025, Madrigal reported positive two-year data from the OLE arm. The results reinforce Rezdiffra’s potential benefit for patients with compensated MASH cirrhosis and support the ongoing MAESTRO-NASH OUTCOMES study's potential success.
Earlier in 2026, Madrigal also added six preclinical siRNA programs to strengthen its pipeline and advance next-generation, genetically targeted MASH therapies alongside Rezdiffra. Such efforts demonstrate MDGL’s commitment to establishing the drug as the standard-of-care treatment for MASH.
Recently, Madrigal expanded its MASH pipeline through a licensing agreement with Arrowhead Pharmaceuticals for global rights to ARO-PNPLA3, a clinical-stage siRNA candidate targeting the genetically validated PNPLA3 mutation linked to MASH. The asset is aimed at a genetically defined patient population representing roughly 30% of moderate-to-advanced fibrosis cases, with phase I data showing up to a 46% reduction in liver fat after a single high dose in PNPLA3 homozygous patients.
Madrigal Pharmaceuticals, Inc. Price, Consensus and EPS SurpriseMadrigal Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Madrigal Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Madrigal Pharmaceuticals, Inc. Quote
MDGL’s Zacks Rank & Stocks to Consider
Madrigal currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals CPRX, Immatics IMTX and Inovio Pharmaceuticals INO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have declined from $2.82 to $2.79. CPRX shares have gained 30.8% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Immatics’ 2026 loss per share have narrowed from $1.61 to $1.49. IMTX shares have gained 9.6% year to date.
Immatics’ earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average negative surprise of 8.06%.
Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 28.8% year to date.
Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report
Madrigal Pharmaceuticals, Inc. (MDGL) : Free Stock Analysis Report
Immatics N.V. (IMTX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
May 7, 2026 · zacks.com
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
- Noteworthy Wednesday Option Activity: SLAB, VCEL, MDGL
May 6, 2026
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Silicon Laboratories Inc (Symbol: SLAB), where a total of 8,212 contracts have traded so far, representing approximately 821,200 underlying shares. That amounts to about 198.3% of SLAB's average daily trading volume over the past month of 414,055 shares. Especially high volume was seen for the $100 strike put option expiring November 20, 2026, with 4,715 contracts trading so far today, representing approximately 471,500 underlying shares of SLAB. Below is a chart showing SLAB's trailing twelve month trading history, with the $100 strike highlighted in orange:
Vericel Corp (Symbol: VCEL) options are showing a volume of 9,378 contracts thus far today. That number of contracts represents approximately 937,800 underlying shares, working out to a sizeable 179.8% of VCEL's average daily trading volume over the past month, of 521,570 shares. Especially high volume was seen for the $35 strike put option expiring May 15, 2026, with 7,219 contracts trading so far today, representing approximately 721,900 underlying shares of VCEL. Below is a chart showing VCEL's trailing twelve month trading history, with the $35 strike highlighted in orange:
And Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw options trading volume of 4,457 contracts, representing approximately 445,700 underlying shares or approximately 174.3% of MDGL's average daily trading volume over the past month, of 255,730 shares. Especially high volume was seen for the $510 strike put option expiring June 18, 2026, with 1,341 contracts trading so far today, representing approximately 134,100 underlying shares of MDGL. Below is a chart showing MDGL's trailing twelve month trading history, with the $510 strike highlighted in orange:
For the various different available expirations for SLAB options, VCEL options, or MDGL options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see: Prem Watsa Stock Picks
CSPI Insider Buying
Top Stocks Held By Bill Ackman
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
May 6, 2026
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby
Strategic Performance and Market Dynamics
Rezdiffra achieved blockbuster status with over $1.1 billion in trailing 12-month net sales, driven by its position as the first-in-disease foundational therapy. Management attributes growth to a 50% expansion of the addressable U.S. market since 2023, fueled by increased diagnosis rates and specialist involvement. Real-world performance is exceeding clinical trial expectations, with prescribers reporting significant improvements in liver stiffness, fat, and enzymes. The company has secured first-line commercial access, which management views as a critical competitive moat against emerging therapies. Strategic positioning focuses on Rezdiffra as a 'backbone' for combinations, assuming that GLP-1s will become a standard background therapy for MASH patients. Operational execution included wiring the system practice-by-practice, moving from hepatologists to a broader base of over 10,000 prescribers including gastroenterologists and endocrinologists.
Growth Outlook and Pipeline Strategy
Management expects to steadily add patients throughout 2026, noting that April 2026 was the best month for new patient starts since launch. The F4C outcomes trial is projected to read out in 2027, potentially doubling the addressable market by expanding the label to include well-compensated cirrhosis. Guidance for gross-to-net discounts is set at the mid-to-high 30s for the remainder of 2026, reflecting stabilized commercial contracting. The R&D strategy is now 'modality-agnostic,' prioritizing the development of combination regimens like the newly licensed siRNA asset for genetically vulnerable populations. Profitability is described as 'inevitable' beyond 2026, though the company will prioritize top-line growth and pipeline investment in the near term.
Financial and Operational Risk Factors
Q1 2026 results were impacted by typical seasonal insurance re-verifications and deductible resets, which management successfully navigated to maintain patient growth. The company recorded $54.3 million in one-time upfront business development expenses in Q1, with an additional $25 million payment for the Arrowhead asset expected in Q2. SG&A expenses are expected to increase in 2026 due to the annualization of the endocrinology sales force and timed marketing campaigns. Management noted that while GLP-1 competition exists, it has not come at the expense of Rezdiffra, as most patients are already on GLP-1s before seeking MASH-specific treatment.
Q&A Session Highlights
Impact of GLP-1 competition and market trends in Q2
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Story Continues
Management clarified that GLP-1s like Wegovy are acting as background therapy rather than competitors, with 25% of Rezdiffra patients currently on a combination. April 2026 was confirmed as the strongest month for new prescriptions (NBRx) since the product's launch.
Rationale for licensing the ARO-PNPLA3 siRNA asset
The asset targets a specific mutation prevalent in 30% of F2-F3 patients, particularly Hispanic populations, who face a twofold higher risk of liver events. Phase I data showed a 46% reduction in liver fat, which Madrigal believes will synergize with Rezdiffra's antifibrotic effects.
Patient staging split between F2 and F3 populations
The patient mix remains a consistent 50-50 split between F2 and F3 stages. Management noted that doctors are not waiting for patients to progress to F3 before initiating therapy due to the risk of rapid progression to cirrhosis.
Path to profitability and full-year financial consensus
Mardi Dier confirmed the company is comfortable with the full-year revenue consensus mentioned by analysts, citing improved gross-to-net visibility. While 2026 will not be profitable due to heavy R&D and SG&A investment, the company is 'preparing for profitability' as a near-term milestone.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
View Comments
- Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
May 6, 2026 · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
